New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 10mg - capsule - 10 mg - active: lenalidomide 10mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf tartrazine titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 15mg - capsule - 15 mg - active: lenalidomide 15mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose tartrazine titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: allura red ac brilliant blue fcf croscarmellose sodium erythrosine gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 25mg - capsule - 25 mg - active: lenalidomide 25mg excipient: croscarmellose sodium gelatin black sw-9007 printing ink lactose magnesium stearate microcrystalline cellulose titanium dioxide water - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: brilliant blue fcf croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose sunset yellow fcf titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: brilliant blue fcf croscarmellose sodium erythrosine gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; hyprolose; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hyprolose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.